AFP is a carrier protein known for transporting nutrients to rapidly growing fetal cells. Only trace amounts of the protein are found following birth, but importantly, receptors for AFP show up again on cancer cells to help shuttle nutrients to rapidly growing cancer cells.
Despite seemingly daily reports of the newest wonder drug that shrinks tumours, gene therapies or even a vaccine there really hasn’t been much progress treating the disease over the last half-century. In 1960, the mortality rate for all cancers combined in the United States was 194 deaths per 100,000 people. In 2009, the mortality rate was 174 deaths for every 100,000 persons.
Alpha Cancer Technologies Inc. (ACT) has created an innovative approach to the advancement of cancer care. Increasing the quality of life is one of the key advantages of a new chemotherapy delivery system that the company is advancing.
The targeting concept is rational and conceptually very attractive – by carrying cytotoxic drugs selectively and specifically to targets on cancer cells, cancer cell killing should be increased and systemic toxicity should be reduced. However, as Dr. Sherman explained, success in this field has been hampered by four major obstacles…